Instructions for Relenza (zanamivir) dosed powder for inhalation
English Product Name
Relenza
Release Form
Inhalation powder dosed
Description Relenza
Inhalation powder dosed from white to almost white.
1 dose
zanamivir (micronized) 5 mg
Auxiliary substances: lactose monohydrate - up to 25 mg.
4 doses - aluminum laminated rotadisks (5) - plastic bottles (1) complete with Diskhaler (1) - cardboard packs.
ATX codes
J05AH01 Zanamivir
Clinical and pharmacological groups / Group affiliation
Antiviral drug
Active ingredient
zanamivir
Pharmacotherapeutic group Relenza
Antiviral agent
Retention conditions
The drug should be stored in a place inaccessible to children at a temperature not exceeding 30 °C.
Expiration date
The shelf life is seven years. Do not apply after expiration of the shelf life indicated on the package.
Pharmacological effect Relenza
"Zanamivir is a potent and selective inhibitor of neuraminidase, an important surface enzyme of influenza virus. This enzyme releases new viral particles from infected cells and allows the virus to cross the mucous barrier to reach the surface of epithelial cells, allowing the infection to spread. Zanamivir is effective in the laboratory and the body against all known subtypes of influenza A virus neuraminidase.
The influenza virus multiplies only in epithelial cells of the respiratory tract. Zanamivir acts in extracellular space and interferes with the spread of both influenza viruses (A and B), preventing infectious viral particles from leaving the respiratory tract epithelial cells. The efficacy of zanamivir on inhalation therapy has been confirmed by clinical trials.
Clinical evidence suggests that the use of zanamivir to treat acute respiratory infections caused by influenza virus has been associated with lower respiratory tract secretions than did placebo. It is important to note that zanamivir does not cause viral strains resistant to its action."
Indications Relenza
- Treatment of infection resulting from influenza A and B viruses is recommended for people older than five years, including adults. In addition, preventive measures against influenza
- A and B virus infection are also important for children over five years of age and adults.
Method of administration and dosage Relenza
The recommended dose of Relense to prevent infections is two inhalations (2×5 mg) once a day for 10 days. The total daily dose is 10 mg. If exposure exceeds 10 days, treatment may be extended to one month. Please apply Relense as prescribed by completing the full prevention course. Dosage does not need to be adjusted in children or in older patients or in patients with renal or liver dysfunction.
- Nosology Relenza (ICD codes)
- J10
- Influenza due to identified seasonal influenza virus